Evaluation of the effect of tibolone and transdermal estradiol on triglyceride level in hypertriglyceridemic and normotriglyceridemic postmenopausal women

Gynecological Endocrinology

Volumn 18, Issue 5, 2004, Pages 233-239

  Dansuk, R ^a,b   Unal, O ^a   Karageyim, Y ^a   Esim, E ^a   Turan, C ^a  

^a Kartal Lutfi Kirdar Education and Research Hospital   (Turkey)

^b NONE   (Turkey)

Author keywords

Hypertriglyceridemia; Tibolone; Transdermal estradiol

Indexed keywords

CHOLESTEROL; ESTRADIOL; LIPID; TIBOLONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR SYSTEM; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; CHOLESTEROL; CHOLESTEROL, HDL; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; HYSTERECTOMY; MIDDLE AGED; NORPREGNENES; POSTMENOPAUSE; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 2942529452     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590410001715199     Document Type: Article

References (13)

1. Genazzani AR, Gambacciani M. Controversial issues in climacteric medicine I. Cardiovascular disease and hormone replacement therapy. International Menopause Society Expert Workshop, 13-16 October 2000, Royal Society of Medicine, London, UK. Climacteric 2000;3:233-40
2. Jousilahti P, Vartiainen E, Tuomilehto J, et al. Sex, age, cardiovascular risk factors and coronary heart disease. Circulation 1999;99:1165-72
3. Mendelsohn ME, Karas RH. Protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-10
4. Stancyzk FZ, Shoupe D, Nunez V, et al. A randomised comparison of non-oral estradiol delivery in post-menopausal women. Am J Obstet Gynecol 1988;159:1540-6
5. Bass KM, Newschaffer CJ, Bush TL. Plasma lipoprotein levels a predictor of cardiovascular death in women. Arch Mem Med 1993;153:2209-16
6. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-19
7. Assmann G, Shuttle H. Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992;70:733
8. Bush TL. The epidemiology of cardiovascular disease in postmenopausal women. Ann NY Acad Sci 1990;592:263-71
9. Heyden S, Heiss G, Hames G, Bartel AG. Fasting triglycerides as predictors of total CHD mortality in Evans Country, Georgia. J Chronic Dis 1980;33:275-82
10. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915
11. Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins and the risk of coronary heart disease. The Framingham Study. Ann Intern Med 1971;74:1-12
12. Lapidus L, Bengtsson C, Lindquist O, et al. Triglycerides - main lipid risk factor for cardiovascular disease in women? Acta Med Scand 1985;217:481-9
13. Kloosterboer HJ, Benedek-Jaszann LJ, Kicovic PM. Long-term effects of Org OD 14 on lipid metabolism in post-menopausal women. Maturitas 1990;12:37-42